[go: up one dir, main page]

CO5261605A1 - PHARMACEUTICAL COMPOUNDS - Google Patents

PHARMACEUTICAL COMPOUNDS

Info

Publication number
CO5261605A1
CO5261605A1 CO00082018A CO00082018A CO5261605A1 CO 5261605 A1 CO5261605 A1 CO 5261605A1 CO 00082018 A CO00082018 A CO 00082018A CO 00082018 A CO00082018 A CO 00082018A CO 5261605 A1 CO5261605 A1 CO 5261605A1
Authority
CO
Colombia
Prior art keywords
alkyl
alkanoyl
group
substituted
alkoxy
Prior art date
Application number
CO00082018A
Other languages
Spanish (es)
Inventor
Jane Ambler Samantha
Baker Stephen Richard
Barry Peter Clark
Stephen Coleman Darrell
Robert James Foglesong
John Goldsworthy
Erik Jagdmann Gunnar Jr
Willis Johnson Kirk
Ann Elizabeth Kigston
William Martin Owton
Darwin Schoepp Darryle
Jian Eric Hong
Jeffrey Michael Schkeryantz
Michael Scott Vannieuwenhz
Sadegh Zia-Ebrahimi Mohammad
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5261605A1 publication Critical patent/CO5261605A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula general <EMI FILE="00082018_1" ID="1" IMF=JPEG >En la queX1 representa O o NH,L representa un enlace o una cadena de alquileno C1-C6 interrumpida opcionalmente por O, S, SO, SO2, o NH y sustituida opcionalmente en un átomo de carbono del alquileno con fluoro, hidroxi, alcoxi C1-C4 u oxo,R1 representa un grupo carbocíclico o heterocíclico sustituido o no sustituidoR2 representa un atomo de hidrógeno, un átomo de halógeno, un grupo carboxilo, un grupo ciano, un SCH2CN, o un grupo de fórmula X2-R5 en la que X2 representa un enlace, O, S, SO, SO2 o NH y R5 representa alquilo C1-C8, cicloalquilo C3-C10, haloalquilo C1-C6, hidroxialquilo C1-C6, dihidroxialquilo C1-C4, (alcoxi C1-C4)(alquilo C1-C4), (alcanoíl C1-C4)(alquilo C1-C4), (alcanoíl C1-C4) oxi (alquilo C1-C4), carboxialquilo C1-C4, (alquil C1-C4) aminocarbonil (alquilo C1-C4), alcanoíl(C1-C4), amino, (alcanoíl C1-C4) amino (alquilo C1-C4), (alcanoíl C1-C4) amino (alquilo C1-C4)2, (alquil C1-C4) tio (alquilo C1-C4), (alquil C1-C4) sufinil (alquilo C1-C4), (alquil C1-C4) sulfonil (alquilo C1-C4), (alquil C1-C4) sulfonilamino (alquilo C1-C4), (alquil C1-C4) aminosulfonil(alquilo C1-C4), (dialquil C1-C4) aminofosfonil (alquilo C1-C4) fenilo o fenialquilo C1-C4, en los que cualquier grupo fenilo no esta sustituido o está sustituido con uno o dos sustituyentes seleccionados independientemente de un átomo de halógeno, alquilo C1-C4 y alcoxi C1-C4, ycada uno de R3 y R4 representa independientemente alquilo C1-C4 o junto con los átomos de carbono a los que están unidos forman un anillo carbocíclico o heterocíclico sustituido o no sustituido, o una sal farmacéuticamente aceptable del mismo para ser usado en la fabricación de un medicamento para el tratamiento de una dolencia que requiera la administración de un antagonista de los receptores mGluR1.A compound of the general formula <EMI FILE = "00082018_1" ID = "1" IMF = JPEG> Where X1 represents O or NH, L represents a C1-C6 alkylene bond or chain optionally interrupted by O, S, SO, SO2, or NH and optionally substituted on an alkylene carbon atom with fluoro, hydroxy, C1-C4 alkoxy or oxo, R1 represents a substituted or unsubstituted carbocyclic or heterocyclic group R2 represents a hydrogen atom, a halogen atom, a group carboxyl, a cyano group, a SCH2CN, or a group of formula X2-R5 in which X2 represents a bond, O, S, SO, SO2 or NH and R5 represents C1-C8 alkyl, C3-C10 cycloalkyl, C1- haloalkyl C6, C1-C6 hydroxyalkyl, C1-C4 dihydroxyalkyl, (C1-C4 alkoxy) (C1-C4 alkyl), (C1-C4 alkanoyl) (C1-C4 alkyl), (C1-C4 alkanoyl) oxy (C1-C4 alkyl ), C1-C4 carboxyalkyl, (C1-C4 alkyl) aminocarbonyl (C1-C4 alkyl), alkanoyl (C1-C4), amino, (C1-C4 alkanoyl) amino (C1-C4 alkyl), (C1-C4 alkanoyl) amino (C1-C4 alkyl) 2, (C1-C4 alkyl) ti or (C1-C4 alkyl), (C1-C4 alkyl) sufinyl (C1-C4 alkyl), (C1-C4 alkyl) sulfonyl (C1-C4 alkyl), (C1-C4 alkyl) sulfonylamino (C1-C4 alkyl), (C1-C4 alkyl) aminosulfonyl (C1-C4 alkyl), (C1-C4 dialkyl) aminophosphonyl (C1-C4 alkyl) phenyl or C1-C4 phenyl alkyl, in which any phenyl group is unsubstituted or substituted with one or two substituents independently selected from a halogen atom, C1-C4 alkyl and C1-C4 alkoxy, and each one of R3 and R4 independently represents C1-C4 alkyl or together with the carbon atoms to which they are attached form a substituted carbocyclic or heterocyclic ring or unsubstituted, or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment of a condition that requires the administration of an mGluR1 receptor antagonist.

CO00082018A 1999-11-01 2000-10-27 PHARMACEUTICAL COMPOUNDS CO5261605A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16290099P 1999-11-01 1999-11-01

Publications (1)

Publication Number Publication Date
CO5261605A1 true CO5261605A1 (en) 2003-03-31

Family

ID=22587589

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00082018A CO5261605A1 (en) 1999-11-01 2000-10-27 PHARMACEUTICAL COMPOUNDS

Country Status (7)

Country Link
EP (1) EP1230225A2 (en)
AR (1) AR026275A1 (en)
AU (1) AU1071301A (en)
CO (1) CO5261605A1 (en)
PE (1) PE20010854A1 (en)
SV (1) SV2002000205A (en)
WO (1) WO2001032632A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2003104230A1 (en) 2002-06-07 2003-12-18 協和醱酵工業株式会社 Bicyclic pyrimidine derivatives
US7423044B2 (en) 2002-09-05 2008-09-09 Wyeth Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia
TW200410975A (en) * 2002-09-26 2004-07-01 Nihon Nohyaku Co Ltd New pesticide and method for using it, new substituted thienopyrimidine derivative, its intermediate, and method for producing it
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
MXPA05005425A (en) * 2002-11-22 2005-11-23 Japan Tobacco Inc Fused bicyclic nitrogen-containing heterocycles.
AU2003288994A1 (en) * 2002-12-10 2004-06-30 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
CA2522522A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds
AU2004229163A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag (6-(phenoxy)-pyrido`3,4-d! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS
JP2007501801A (en) 2003-08-07 2007-02-01 日本たばこ産業株式会社 Pyrrolo [1,2-b] pyridazine derivatives
WO2005016925A1 (en) * 2003-08-14 2005-02-24 Pfizer Limited Azaquinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20070197510A1 (en) * 2004-03-10 2007-08-23 Kazuyuki Ohmoto Nitriles and medicinal compositions containing the same as the active ingredient
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
AR049300A1 (en) 2004-06-15 2006-07-12 Schering Corp MGLUR1 ANTAGONIST TRICICLIC COMPOUNDS AS THERAPEUTIC AGENTS
ATE485300T1 (en) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc THIENOPYRIMIDINES USABLE AS AURORA KINASE INHIBITORS
WO2006028904A1 (en) * 2004-09-02 2006-03-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
HUP0501170A2 (en) * 2005-12-20 2007-09-28 Richter Gedeon Nyrt 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
HUP0501168A3 (en) * 2005-12-20 2007-10-29 Richter Gedeon Nyrt 2-(acyl, oxycarbonyl or aminocarbonyl)-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical composition containing them
JP2009520016A (en) * 2005-12-20 2009-05-21 リヒター ゲデオン ニュルト New compounds
CA2630896A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
RU2441869C2 (en) 2005-12-21 2012-02-10 Эбботт Лэборетриз Antiviral compouds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
EP1979349B1 (en) 2005-12-21 2010-07-28 Abbott Laboratories Anti-viral compounds
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
DE102006012251A1 (en) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
RS55585B1 (en) 2006-11-22 2017-06-30 Clinical Research Associates LLC PROCEDURES FOR TREATMENT OF DOWN SYNDROME, FLEXIBLE X SYNDROME AND AUTISM
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
EA200901041A1 (en) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх BICYCLIC HETEROCYCLES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD OF OBTAINING THEM
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CN101821256A (en) 2007-08-02 2010-09-01 瑞蔻达蒂爱尔兰有限公司 Novel heterocyclic compounds as mGlu5 antagonists
EP2203439B1 (en) 2007-09-14 2011-01-26 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-ý1, 4'¨bipyridinyl-2'-ones
CN101848893B (en) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
RS52573B (en) 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh SPIROCYCLIC HETEROCYCLES, THE MEDICINAL PRODUCTS CONTAINING THIS UNIT, THEIR APPLICATION AND THE PROCEDURE FOR THEIR MANUFACTURING
BRPI0912170A2 (en) 2008-05-13 2015-10-13 Astrazeneca Ab compound, form, process for preparation thereof, pharmaceutical composition, use of a compound, and method for treating cancer in a warm-blooded animal
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
MX2011002042A (en) 2008-09-02 2011-06-20 Ortho Mcneil Janssen Pharm 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors.
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
JP5539376B2 (en) * 2008-11-19 2014-07-02 エボテック （ユーエス） インコーポレイテッド 6,7-Dihydro-5H-pyrrolo [3,4-D] pyrimidin-4-yl] quinolin-3-ylamine compounds useful as FAAH modulators and uses thereof
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
NZ593110A (en) * 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
EP2393780A1 (en) 2009-02-04 2011-12-14 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5707390B2 (en) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
EP2430022B1 (en) 2009-05-12 2013-11-20 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
WO2011106276A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
JP2013529673A (en) 2010-07-09 2013-07-22 レコルダーティ アイルランド リミテッド Novel spiroheterocyclic compounds as MGLU5 antagonists
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
MX2013003913A (en) 2010-10-08 2013-09-26 Abbvie Inc FURO[3,2-d]PYRIMIDINE COMPOUNDS.
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
TWI499591B (en) * 2013-01-11 2015-09-11 Lilly Co Eli Bicyclic pyrimidine compounds
TW201520219A (en) * 2013-03-12 2015-06-01 Lilly Co Eli Imidazo pyridine compounds
TW201500356A (en) * 2013-04-12 2015-01-01 Lilly Co Eli Dihydropyrido pyrimidine compounds
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors.
AU2014287016B2 (en) 2013-07-11 2018-11-01 Acea Biosciences Inc. Pyrimidine derivatives as kinase inhibitors
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ME03518B (en) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv COMBINATIONS INCLUDING POSITIVE ALOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR APPLICATIONS
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
JP2018525345A (en) * 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ Substituted quinazoline compounds and their use for modulation of glucocerebrosidase activity
WO2017014323A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
WO2017059702A1 (en) 2015-10-09 2017-04-13 Acea Biosciences, Inc Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
JP2020516682A (en) 2017-04-07 2020-06-11 エイシア セラピューティクス， インコーポレイテッド Pharmaceutical salts, physical forms and compositions of pyrrolopyrimidine kinase, and methods of making the same
EP4151616A4 (en) * 2021-04-26 2023-12-20 Mitsubishi Gas Chemical Company, Inc. COMPOUND AND PRODUCTION METHOD THEREFOR
WO2025188973A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes
WO2025188952A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582407A (en) * 1977-06-07 1981-01-07 Worcester Controls Uk Ltd Annular seals
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
PT100905A (en) * 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
GB9823845D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
DE19904710A1 (en) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical compositions containing them
SE9903290D0 (en) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
SV2002000205A (en) 2002-06-07
WO2001032632A2 (en) 2001-05-10
AR026275A1 (en) 2003-02-05
EP1230225A2 (en) 2002-08-14
WO2001032632A3 (en) 2001-11-08
AU1071301A (en) 2001-05-14
PE20010854A1 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
CO5261605A1 (en) PHARMACEUTICAL COMPOUNDS
AR016817A1 (en) DERIVATIVES OF FENILUREA OR FENILTIOUREA, PROCEDURE FOR PREPARATION, COLLECTION OF COMPOUNDS, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
CO5031253A1 (en) RECEIVING ANTAGONISTS Y5 OF NEUROPEPTIDES PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO5251381A1 (en) ADAMANTAN DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY24206A1 (en) ALPHA 1L PHENYLIMINOIMIDAZOLINES AGONISTS USEFUL IN THE TREATMENT OF URINARY INCONTINENCE.
NO914528L (en) N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
KR960014121A (en) Aroyl-piperidine derivatives
CO5070570A1 (en) THYROSINE DERIVATIVES AS ACTIVATORS OF hPPAR AND hPPARALFA AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM
CO5450245A1 (en) CHEMICAL COMPOUNDS WITH DOUBLE ACTIVITY, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS
CO5261526A1 (en) NEW COMPOUNDS
AR005706A1 (en) EGFR INHIBITORS OF 4-AMINOQUINZOLINE, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, USE OF THE SAME FOR THE PREPARATION OF A MEDICINE USEFUL AS AN ANTINEOPLASTIC AGENT
BR0208678A (en) Compound, pharmaceutical composition, use of a compound
RU2502730C2 (en) Sulphonamide compounds and use thereof
CO5180622A1 (en) COMPOUND 2- {2-METHYL-4 - [({4-METHYL-2 [4- (TRIFLUOROMETIL) PHENYL] -1,3-TIAZOL-5-IL] METHYL) SULFONYL] PHENOXY] ACETIC AND PHARMACEUTICAL COMPOSITION THAT INCLUDES
RU2000105266A (en) 1- (N-Phenylaminoalkyl) -piperazine derivatives Substituted in Position 2 of the Phenyl Ring
AR046244A1 (en) HETEROAROMATIC GLUCOQUINASE ACTIVATORS OF SIX MEMBERS 5- REPLACED
AR033735A1 (en) ALFA-AMINO ACIDS COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO5180629A1 (en) PYRIMIDINE-2,4,6-METALOPROTEINASE INHIBITING TTRIONS
NO20081970L (en) Sulfonamide derivatives with PGD2 receptor antagonist activity
BR0307409A (en) 2-Furanecarboxylic acid hydrazide compounds, pharmaceutical compositions containing them and use thereof for the preparation of a preventive or therapeutic agent
CO5261565A1 (en) INHIBITORS OF N- (5 - (((5-RENT-2-OXAZOLIL) METHYL) TIO) -2-TIAZOLIL) -CARBOXAMIDE OF CYCLINE DEPENDENT KINASES
PE20050420A1 (en) PHENACILO 2-HYDROXY-3-DIAMINOALKANOS
DK0759919T3 (en) Azolidinediones as antihyperglycemic agents
EA200200119A1 (en) β-CARBOLINE DRUGS
DK1189900T3 (en) Heterocyclic aminopyrrolidine derivatives as melatonergic drugs